$9.89
0.66% today
Nasdaq, Feb 28, 04:48 pm CET
ISIN
US64049M2098
Symbol
NEO

NeoGenomics, Inc. Stock price

$9.82
-5.22 34.71% 1M
-6.57 40.09% 6M
-6.66 40.41% YTD
-6.31 39.12% 1Y
-11.59 54.13% 3Y
-17.69 64.30% 5Y
+5.28 116.30% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.58 5.58%
ISIN
US64049M2098
Symbol
NEO
Sector

Key metrics

Market capitalization $1.26b
Enterprise Value $1.48b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.24
P/S ratio (TTM) P/S ratio 1.91
P/B ratio (TTM) P/B ratio 1.39
Revenue growth (TTM) Revenue growth 11.65%
Revenue (TTM) Revenue $660.57m
EBIT (operating result TTM) EBIT $-84.05m
Free Cash Flow (TTM) Free Cash Flow $-34.04m
Cash position $386.84m
EPS (TTM) EPS $-0.62
P/E forward negative
P/S forward 1.71
EV/Sales forward 2.01
Short interest 3.71%
Show more

Is NeoGenomics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

NeoGenomics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a NeoGenomics, Inc. forecast:

10x Buy
67%
5x Hold
33%

Analyst Opinions

15 Analysts have issued a NeoGenomics, Inc. forecast:

Buy
67%
Hold
33%

Financial data from NeoGenomics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
661 661
12% 12%
100%
- Direct Costs 389 389
6% 6%
59%
271 271
21% 21%
41%
- Selling and Administrative Expenses 252 252
16% 16%
38%
- Research and Development Expense 31 31
14% 14%
5%
-12 -12
41% 41%
-2%
- Depreciation and Amortization 73 73
6% 6%
11%
EBIT (Operating Income) EBIT -84 -84
13% 13%
-13%
Net Profit -79 -79
11% 11%
-12%

In millions USD.

Don't miss a Thing! We will send you all news about NeoGenomics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeoGenomics, Inc. Stock News

Negative
Seeking Alpha
about 8 hours ago
NeoGenomics is rated a Hold due to the intrinsic value being lower than the current price, and the company's negative net income and FCF. Despite revenue growth and increasing clinical volume, NeoGenomics missed revenue estimates, causing a 15.50% drop in the stock price. NeoGenomics shows promising long-term growth potential with rising cancer cases and improving ROIC, but negative profitabili...
Neutral
Business Wire
4 days ago
FT. MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in several upcoming investor conferences.
Neutral
Seeking Alpha
10 days ago
NeoGenomics, Inc (NASDAQ:NEO ) Q4 2024 Earnings Conference Call February 18, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Chris Smith - Chief Executive Officer Warren Stone - Chief Commercial Officer Andrew Lukowiak - Chief Innovation Officer Jeffrey Sherman - Chief Financial Officer Kareem Saad - Head, Strategy and Transformation Nate Montgom...
More NeoGenomics, Inc. News

Company Profile

NeoGenomics, Inc. is a clinical laboratory company, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Head office United States
CEO Chris Smith
Employees 2,200
Founded 1998
Website www.neogenomics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today